Chemomab Therapeutics Ltd.
CMMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534248
In the last 90 days, Chemomab Therapeutics Ltd. insiders filed 0 open-market purchases and 1 sale; 13 institutions reported holding it in 13F filings for Q2 2026, worth $615.3K in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Chemomab Therapeutics Ltd. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 13
- −1 vs. Q4 2022
- Shares held
- 2.89M
- −423.7K (−12.8%) vs. Q4 2022
- Total value
- $4.56M
- −$6.04M (−57.0%) vs. Q4 2022
- New holders
- 2
- 1 more added
- Sold out
- 3
- 5 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CMMB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 13 | $615.3K |
| Q1 2026 | 15 | $551.9K |
| Q4 2025 | 14 | $606.1K |
| Q3 2025 | 10 | $1.03M |
| Q2 2025 | 14 | $4.91M |
| Q1 2025 | 17 | $4.07M |
| Q4 2024 | 16 | $7.53M |
| Q3 2024 | 15 | $7.14M |
| Q2 2024 | 15 | $2.44M |
| Q1 2024 | 14 | $2.07M |
| Q4 2023 | 16 | $1.43M |
| Q3 2023 | 11 | $2.26M |
| Q2 2023 | 11 | $3.33M |
| Q1 2023 | 13 | $4.56M |
| Q4 2022 | 14 | $10.6M |
| Q3 2022 | 15 | $8.09M |
| Q2 2022 | 13 | $12.2M |
| Q1 2022 | 15 | $15.9M |
| Q4 2021 | 14 | $22.7M |
| Q3 2021 | 15 | $35.9M |
| Q2 2021 | 12 | $58.7M |
| Q1 2021 | 10 | $82.6M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Chemomab Therapeutics Ltd.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 246 | $0 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 411 | $653 | 0.00% | −4,218−91.1% | Reduced |
| Newbridge Financial Services Group, Inc. | 1,100 | $1.75K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 2,725 | $4.33K | 0.00% | −3,649−57.2% | Reduced |
| Morgan Stanley | 7,800 | $12.4K | 0.00% | +1,200+18.2% | Added |
| Geode Capital Management, LLC | 11,737 | $18.7K | 0.00% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 11,800 | $18.8K | 0.00% | +11,800 | New |
| Boothbay Fund Management, LLC | 26,529 | $42.2K | 0.00% | −25,079−48.6% | Reduced |
| Two Sigma Investments, LP | 30,263 | $48.1K | 0.00% | +30,263 | New |
| Kestra Private Wealth Services, LLC | 31,241 | $49.7K | 0.00% | 00.0% | Unchanged |
| Ikarian Capital, LLC | 236,709 | $342.1K | 0.14% | −76,683−24.5% | Reduced |
| Cormorant Asset Management, LP | 288,169 | $458.0K | 0.03% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 2,241,274 | $3.56M | 0.07% | −336,900−13.1% | Reduced |
| Envestnet Asset Management Inc | 0 | $0 | 0.00% | −12,861−100.0% | Sold out |
| Activest Wealth Management | 0 | $0 | 0.00% | −7,600−100.0% | Sold out |
| Credit Suisse AG | 0 | $0 | 0.00% | −1−100.0% | Sold out |